De novo CD5 + diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients

Motoko Yamaguchi, Masao Seto, Masataka Okamoto, Ryo Ichinohasama, Naoya Nakamura, Tadashi Yoshino, Junji Suzumiya, Takuhei Murase, Ikuo Miura, Takashi Akasaka, Jun Ichi Tamaru, Ritsuro Suzuki, Yoshitoyo Kagami, Masami Hirano, Yasuo Morishima, Ryuzo Ueda, Hiroshi Shiku, Shigeo Nakamura

Research output: Contribution to journalArticlepeer-review

248 Citations (Scopus)


De novo CD5 + diffuse large B-cell lymphoma (CD5 + DLBCL) is known to have phenotypically and genotypically different characteristics than CD5 - DLBCL and mantle cell lymphoma (MCL). To further characterize CD5 + DLBCL, 109 patients with CD5 + DLBCL were reviewed, and the results were compared with those of 384 CD5 - DLBCL and 128 cyclin D1 + MCL patients. Patients with CD5 + DLBCL showed a higher age distribution (median, 66 years; P = .0083) and a female predominance (male-female ratio, 49:60, P = .011) compared with those with CD5 - DLBCL. CD5 + DLBCL was more closely associated with many aggressive clinical features or parameters than CD5 - DLBCL: 69% older than 60 years (P = .039), 34% with performance status greater than 1 (P = .0016), 69% with serum lactate dehydrogenase level higher than normal (P < .0001), 62% with stage III/IV disease at diagnosis (P = .0023), 35% with more than one extranodal site (P = .023), and 40% with B symptoms (P = .0031). The overall International Prognostic Index score was thus significantly higher for the patients with CD5 + DLBCL than for those with CD5 - DLBCL (P = .00005). The most frequent site of extranodal involvement was bone marrow (28%), a higher frequency than that for CD5 - DLBCL (P < .0001) but lower than that for cyclin D1 + MCL (P = .0015). Histopathologically, CD5 + DLBCL showed centroblastic morphology except for 3 patients with immunoblastic disease, and interfollicular growth pattern (7%) and intravascular or intrasinusoidal infiltration (19%) were observed. Immunophenotypically, CD5 + DLBCL was characterized by a CD5 +CD10 -CD19 + CD20 +CD21 -CD23 - cyclin D1 - phenotype and a predominance of surface IgMκ. Of particular interest is that CD5 + DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5 - DLBCL (P = .0026). These findings suggest that CD5 + DLBCL may constitute a unique subgroup of DLBCL.

Original languageEnglish
Pages (from-to)815-821
Number of pages7
Issue number3
Publication statusPublished - Feb 1 2002

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'De novo CD5 + diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients'. Together they form a unique fingerprint.

Cite this